Home › Trials › NCT07919236
Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin

Official title: Continuous Glucose Monitoring Systems in People With Type 2 Diabetes Not Treated With Insulin - the Association With Metabolic Control of Diabetes and Markers of Early Vascular Changes

Run by Medical University of Bialystok · NCT07919236 · Data updated 2026-11-12

This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.

More Type 2 Diabetes trials

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment50 (estimated)
SponsorMedical University of Bialystok
Academic / other
Drugs / interventionsChemotherapy
Locations1 site (Bialystok)
StatusRecruiting
StartedNovember 2026
Main results expectedFebruary 2028
Study endsMay 2028
Registry record updatedNovember 5, 2026
Trial IDNCT07919236 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 18–65 with type 2 diabetes for at least 6 months, BMI ≥25 kg/m2, on oral meds or GLP-1 receptor agonists or tirzepatide, HbA1c 7.5–10%, and no recent insulin therapy or CGM use.

Probably not a fit

Individuals with HbA1c >10% or those on insulin, or with conditions preventing CGM sensor use, may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults aged 18–65 with type 2 diabetes and overweight/obesity, treated with non-insulin regimens, will be randomized to use a CGM system or self-monitoring with a glucose meter for 12 weeks. The study will track metabolic control (HbA1c and related markers) and quality of life, plus explore links between glucose control and early cardiovascular disease markers. Follow-up occurs 3 months after the intervention to see if benefits persist. The trial compares CGM use to standard capillary glucose monitoring in routine care.

Why it matters

Potential benefit: If successful, CGM could help patients better manage blood sugar and potentially reduce cardiovascular risk.

How similar studies have gone: Past studies show CGM benefits in insulin-treated diabetes, but evidence in non-insulin-treated type 2 diabetes is limited and exploratory here.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age between 18 and 65 years (both inclusive)
* Type 2 diabetes diagnosed at least 6 months prior to entering the study
* Body mass index ≥25 kg/m2
* Diabetes treated with oral medications and/or GLP-1 receptor agonists and/or tirzepatide
* No modifications of diabetes treatment in the previous 3 months
* HbA1c between 7.5% and 10% (both inclusive)
* Oral and written informed consent for participation

Exclusion Criteria:

* Type 1 diabetes, gestational diabetes, other specific types of diabetes
* HbA1c \>10.0%
* Treatment with insulin
* Previous use of any continuous glucose monitoring system
* GFR \<30 ml/min
* Acute infections, acute diabetes complications and/or unplanned hospitalisations in the previous month
* Use of steroids or immunosuppressive medications in the previous 3 months
* Chemotherapy, radiotherapy, immune therapy in the previous 3 months
* Pregnancy and/or breastfeeding
* Skin lesions or dermatological conditions preventing proper sensor insertion
* Cognitive impairment and/or other conditions preventing proper use of continuous glucose monitoring system
* Lack of consent for the use of continuous glucose monitoring system

Where it's running

  • Medical University of Bialystok, Department of Internal Medicine and Metabolic Diseases
    Bialystok, Poland     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Type 2 Diabetes 581Medical University of Bialystok 14
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.